Cambria Pharmaceuticals, Inc. Garners $5,400,000 Series A Funding
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3818e85e-0d92-460c-9bbc-bfdacbcf7efa&Preview=1
Date 4/22/2008
Company Name Cambria Pharmaceuticals, Inc.
Mailing Address 8A Henshaw St Woburn, MA 01801
Company Description Cambria Pharmaceuticals is focused on the discovery of innovative treatments for serious and progressively disabling neurological disorders. The Company exploits recent discoveries in the genetic basis of these disorders to engineer novel disease models and identify first-in-class, disease-modifying compounds. Cambria leverages collaborative relationships with academic institutions and patient-focused foundations to advance its programs in ALS (Lou Gehrig’s disease) and other serious neurological diseases.
Proceeds Purposes This investment will be used, along with a comparable amount of venture philanthropy funding that we have previously obtained, to advance our lead program in ALS, as well as drug discovery efforts for other serious neurological disorders,” stated Leo Liu, M.D., President and CEO.
Share
